Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients
Open Access
- 1 July 1998
- journal article
- clinical trial
- Published by Springer Nature in British Journal of Cancer
- Vol. 78 (1) , 34-39
- https://doi.org/10.1038/bjc.1998.438
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- High-performance liquid chromatographic procedure for the quantitative determination of paclitaxel (Taxol®) in human plasmaJournal of Chromatography B: Biomedical Sciences and Applications, 1993
- Measurement of Cremophor EL Following Taxol: Plasma Levels Sufficient to Reverse Drug Exclusion Mediated by the Multidrug-Resistant PhenotypeJNCI Journal of the National Cancer Institute, 1993
- Clinical toxicities encountered with paclitaxel (Taxol).1993
- Risk Factors Linked to Tumor Recurrence of Human Hepatocellular Carcinoma After Hepatic ResectionHepatology, 1992
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989
- Expression of Multidrug Resistance Gene in Human CancersJNCI Journal of the National Cancer Institute, 1989
- Phase II study of mitoxantrone in unresectable primary hepatocellular carcinoma following hepatitis B infectionCancer Chemotherapy and Pharmacology, 1989
- PREDICTION OF THE SAFE LIMITS OF HEPATECTOMY BY COMBINED VOLUMETRIC AND FUNCTIONAL MEASUREMENTS IN PATIENTS WITH IMPAIRED HEPATIC-FUNCTION1984
- The application of statistical moment theory to the evaluation ofin vivo dissolution time and absorption timeJournal of Pharmacokinetics and Biopharmaceutics, 1980
- Hepatitis-Associated Antigen and Hepatocellular Carcinoma in TaiwanAnnals of Internal Medicine, 1971